Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Darron Cummings / AP
Pharmaceutical giant Eli Lilly is facing civil investigations from attorneys general in New Mexico and Washington into its insulin prices, according to Lilly's latest quarterly filing. Washington's attorney general is also looking into Lilly's relationships with pharmacy benefit mangers — the middlemen who negotiate drug prices for insurance companies and employers.
Why this matters: The filing did not give details about the probes. But Lilly has already been in hot water over the rising prices of its insulin medications. A separate class-action lawsuit from earlier this year accused Lilly and two other insulin makers of colluding to jack up prices together. The lawsuit also alleged that the drug companies and pharmacy benefit managers are exploiting the pricing system to benefit each other. Lilly said it is cooperating with both state investigations.